Free Trial

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amgen Inc. stock logo
AMGN
Amgen
$312.47
-0.7%
$281.36
$211.71
$329.72
$167.62B0.62.98 million shs1.97 million shs
Activision Blizzard, Inc. stock logo
ATVI
Activision Blizzard
$94.42
$93.80
$70.94
$94.57
$74.29B0.448.31 million shs1 shs
Microsoft Co. stock logo
MSFT
Microsoft
$420.21
-0.2%
$415.05
$309.45
$430.82
$3.12T0.8920.31 million shs15.35 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$28.64
-1.0%
$27.20
$25.20
$40.37
$162.29B0.6345.22 million shs26.11 million shs
Seagen Inc. stock logo
SGEN
Seagen
$228.74
$228.74
$123.77
$228.96
$42.93B0.321.48 million shs86 shs
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amgen Inc. stock logo
AMGN
Amgen
0.00%+0.75%+18.92%+10.14%+38.86%
Activision Blizzard, Inc. stock logo
ATVI
Activision Blizzard
0.00%0.00%0.00%0.00%+21.22%
Microsoft Co. stock logo
MSFT
Microsoft
0.00%+1.32%+3.94%+4.00%+33.82%
Pfizer Inc. stock logo
PFE
Pfizer
-0.02%+2.25%+12.82%+3.69%-22.07%
Seagen Inc. stock logo
SGEN
Seagen
0.00%0.00%0.00%0.00%+18.49%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Amgen Inc. stock logo
AMGN
Amgen
4.8009 of 5 stars
2.34.03.33.93.72.51.9
Activision Blizzard, Inc. stock logo
ATVI
Activision Blizzard
0.5735 of 5 stars
1.00.02.52.10.61.71.3
Microsoft Co. stock logo
MSFT
Microsoft
4.8484 of 5 stars
2.55.03.32.92.52.52.5
Pfizer Inc. stock logo
PFE
Pfizer
4.9959 of 5 stars
4.25.04.24.82.51.71.9
Seagen Inc. stock logo
SGEN
Seagen
0.2564 of 5 stars
1.00.00.02.50.03.30.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Amgen Inc. stock logo
AMGN
Amgen
2.52
Moderate Buy$305.65-2.18% Downside
Activision Blizzard, Inc. stock logo
ATVI
Activision Blizzard
2.06
Hold$94.36-0.07% Downside
Microsoft Co. stock logo
MSFT
Microsoft
2.94
Moderate Buy$454.708.21% Upside
Pfizer Inc. stock logo
PFE
Pfizer
2.40
Hold$35.8625.20% Upside
Seagen Inc. stock logo
SGEN
Seagen
2.00
Hold$229.000.11% Upside

Current Analyst Ratings

Latest ATVI, AMGN, MSFT, PFE, and SGEN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/17/2024
Microsoft Co. stock logo
MSFT
Microsoft
Macquarie
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$460.00 ➝ $475.00
5/17/2024
Microsoft Co. stock logo
MSFT
Microsoft
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$450.00 ➝ $500.00
5/9/2024
Amgen Inc. stock logo
AMGN
Amgen
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$223.00 ➝ $235.00
5/3/2024
Amgen Inc. stock logo
AMGN
Amgen
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$284.00 ➝ $307.00
5/3/2024
Amgen Inc. stock logo
AMGN
Amgen
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$271.00 ➝ $310.00
5/3/2024
Amgen Inc. stock logo
AMGN
Amgen
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$332.00 ➝ $328.00
5/3/2024
Amgen Inc. stock logo
AMGN
Amgen
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$336.00 ➝ $355.00
5/3/2024
Amgen Inc. stock logo
AMGN
Amgen
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeUnderweight ➝ Equal Weight$230.00 ➝ $300.00
5/3/2024
Amgen Inc. stock logo
AMGN
Amgen
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeMarket Perform ➝ Outperform
5/2/2024
Pfizer Inc. stock logo
PFE
Pfizer
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$28.00 ➝ $29.00
5/2/2024
Pfizer Inc. stock logo
PFE
Pfizer
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$33.00 ➝ $36.00
(Data available from 5/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Amgen Inc. stock logo
AMGN
Amgen
$28.19B5.95$26.35 per share11.86$9.36 per share33.38
Activision Blizzard, Inc. stock logo
ATVI
Activision Blizzard
$8.71B8.53$3.38 per share27.91$24.59 per share3.84
Microsoft Co. stock logo
MSFT
Microsoft
$211.92B14.74$11.73 per share35.82$34.06 per share12.34
Pfizer Inc. stock logo
PFE
Pfizer
$58.50B2.77$2.98 per share9.62$16.33 per share1.75
Seagen Inc. stock logo
SGEN
Seagen
$2.30B18.66N/AN/A$15.10 per share15.15

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Amgen Inc. stock logo
AMGN
Amgen
$6.72B$7.0044.6415.182.8112.74%156.21%10.82%8/1/2024 (Estimated)
Activision Blizzard, Inc. stock logo
ATVI
Activision Blizzard
$1.51B$2.7334.5924.092.6124.87%14.87%10.78%N/A
Microsoft Co. stock logo
MSFT
Microsoft
$72.36B$11.5536.3831.882.2236.43%37.54%19.02%7/23/2024 (Estimated)
Pfizer Inc. stock logo
PFE
Pfizer
$2.12B-$0.06N/A10.381.21-0.56%8.64%3.70%8/6/2024 (Estimated)
Seagen Inc. stock logo
SGEN
Seagen
-$610.31M-$4.01N/AN/AN/A-32.61%-28.06%-20.92%N/A

Latest ATVI, AMGN, MSFT, PFE, and SGEN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/2/2024Q1 2024
Amgen Inc. stock logo
AMGN
Amgen
$3.76$3.96+$0.20$8.13$7.45 billion$7.45 billion    
5/1/2024Q1 2024
Pfizer Inc. stock logo
PFE
Pfizer
$0.56$0.82+$0.26$1.09$13.87 billion$14.88 billion    
4/25/2024Q3 2024
Microsoft Co. stock logo
MSFT
Microsoft
$2.81$2.94+$0.13$2.94$60.86 billion$61.86 billion    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Amgen Inc. stock logo
AMGN
Amgen
$9.002.88%+10.01%128.57%13 Years
Activision Blizzard, Inc. stock logo
ATVI
Activision Blizzard
$0.991.05%N/A36.26%1 Years
Microsoft Co. stock logo
MSFT
Microsoft
$3.000.71%+10.11%25.97%22 Years
Pfizer Inc. stock logo
PFE
Pfizer
$1.685.87%+2.57%N/A 15 Years
Seagen Inc. stock logo
SGEN
Seagen
N/AN/AN/AN/AN/A

Latest ATVI, AMGN, MSFT, PFE, and SGEN Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/24/2024
Pfizer Inc. stock logo
PFE
Pfizer
quarterly$0.426.4%5/9/20245/10/20246/14/2024
3/12/2024
Microsoft Co. stock logo
MSFT
Microsoft
quarterly$0.750.72%5/15/20245/16/20246/13/2024
3/6/2024
Amgen Inc. stock logo
AMGN
Amgen
quarterly$2.253.25%5/16/20245/17/20246/7/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Amgen Inc. stock logo
AMGN
Amgen
11.96
1.42
0.98
Activision Blizzard, Inc. stock logo
ATVI
Activision Blizzard
0.17
4.66
4.66
Microsoft Co. stock logo
MSFT
Microsoft
0.17
1.24
1.23
Pfizer Inc. stock logo
PFE
Pfizer
0.66
1.05
0.78
Seagen Inc. stock logo
SGEN
Seagen
N/A
2.67
2.12

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Amgen Inc. stock logo
AMGN
Amgen
76.50%
Activision Blizzard, Inc. stock logo
ATVI
Activision Blizzard
81.93%
Microsoft Co. stock logo
MSFT
Microsoft
71.13%
Pfizer Inc. stock logo
PFE
Pfizer
68.36%
Seagen Inc. stock logo
SGEN
Seagen
84.26%

Insider Ownership

CompanyInsider Ownership
Amgen Inc. stock logo
AMGN
Amgen
0.69%
Activision Blizzard, Inc. stock logo
ATVI
Activision Blizzard
1.08%
Microsoft Co. stock logo
MSFT
Microsoft
0.03%
Pfizer Inc. stock logo
PFE
Pfizer
0.06%
Seagen Inc. stock logo
SGEN
Seagen
25.90%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Amgen Inc. stock logo
AMGN
Amgen
26,700536.43 million532.73 millionOptionable
Activision Blizzard, Inc. stock logo
ATVI
Activision Blizzard
13,000786.80 million778.30 millionOptionable
Microsoft Co. stock logo
MSFT
Microsoft
221,0007.43 billion7.43 billionOptionable
Pfizer Inc. stock logo
PFE
Pfizer
88,0005.67 billion5.66 billionOptionable
Seagen Inc. stock logo
SGEN
Seagen
3,256187.70 million139.08 millionOptionable

ATVI, AMGN, MSFT, PFE, and SGEN Headlines

Recent News About These Companies

MRNA Feb 2024 64.000 put
MRNA Feb 2024 77.000 call
MRNA Feb 2024 67.000 put
SGEN Jan 2024 210.000 put
SGEN Jan 2024 235.000 put(CONTR
SGEN Dec 2023 195.000 put(CONTR
HBM Gets Health Boost From Drug Licensing Deals

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Amgen logo

Amgen

NASDAQ:AMGN
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Activision Blizzard logo

Activision Blizzard

NASDAQ:ATVI
Activision Blizzard, Inc., together with its subsidiaries, develops and publishes interactive entertainment content and services in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates through three segments: Activision, Blizzard, and King. It develops and distributes content and services on video game consoles, personal computers, and mobile devices, including subscription, full-game, and in-game sales, as well as by licensing software to third-party or related-party companies that distribute Activision and Blizzard products. The company also maintains a proprietary online gaming service, Battle.net that facilitates digital distribution of content, online social connectivity, and the creation of user-generated content. In addition, it operates esports leagues and offer digital advertising content; and provides warehousing, logistics, and sales distribution services to third-party publishers of interactive entertainment software, as well as manufacturers of interactive entertainment hardware products. The company's key product franchises include Call of Duty, World of Warcraft, Diablo, Hearthstone, Overwatch, Overwatch League, and Candy Crush. It serves retailers and distributors, including mass-market retailers, consumer electronics stores, discount warehouses, and game specialty stores through third-party distribution and licensing arrangements. The company was founded in 1979 and is headquartered in Santa Monica, California.
Microsoft logo

Microsoft

NASDAQ:MSFT
Microsoft Corporation develops and supports software, services, devices and solutions worldwide. The Productivity and Business Processes segment offers office, exchange, SharePoint, Microsoft Teams, office 365 Security and Compliance, Microsoft viva, and Microsoft 365 copilot; and office consumer services, such as Microsoft 365 consumer subscriptions, Office licensed on-premises, and other office services. This segment also provides LinkedIn; and dynamics business solutions, including Dynamics 365, a set of intelligent, cloud-based applications across ERP, CRM, power apps, and power automate; and on-premises ERP and CRM applications. The Intelligent Cloud segment offers server products and cloud services, such as azure and other cloud services; SQL and windows server, visual studio, system center, and related client access licenses, as well as nuance and GitHub; and enterprise services including enterprise support services, industry solutions, and nuance professional services. The More Personal Computing segment offers Windows, including windows OEM licensing and other non-volume licensing of the Windows operating system; Windows commercial comprising volume licensing of the Windows operating system, windows cloud services, and other Windows commercial offerings; patent licensing; and windows Internet of Things; and devices, such as surface, HoloLens, and PC accessories. Additionally, this segment provides gaming, which includes Xbox hardware and content, and first- and third-party content; Xbox game pass and other subscriptions, cloud gaming, advertising, third-party disc royalties, and other cloud services; and search and news advertising, which includes Bing, Microsoft News and Edge, and third-party affiliates. The company sells its products through OEMs, distributors, and resellers; and directly through digital marketplaces, online, and retail stores. The company was founded in 1975 and is headquartered in Redmond, Washington.
Pfizer logo

Pfizer

NYSE:PFE
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Seagen logo

Seagen

NASDAQ:SGEN
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. It offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of adult patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. The company also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-TGT and SEA-CD70 for various cancer diseases. It has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington. As of December 14, 2023, Seagen Inc. operates as a subsidiary of Pfizer Inc.